Phase II Randomized Placebo-controlled Study With Vitamin K2 in Asymptomatic Calcified Carotid Stenosis (SCAVIT-K2)
Primary Purpose
Carotid Disease, Atherosclerosis
Status
Unknown status
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Vitamin K2 (Menaquinone)
Sponsored by
About this trial
This is an interventional treatment trial for Carotid Disease
Eligibility Criteria
Inclusion Criteria:
- carotid stenosis between 50 and 70% (NASCET criteria) with calcified plaque
Exclusion Criteria:
- renal and/or hepatic failure
- diseases with secondary calcifications
- dementia
- previous strokes
- concomitant use of anticoagulants
- concomitant infections
- pregnancy or breastfeeding
- reduced patient's compliance
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Vitamin K2
Arm Description
Outcomes
Primary Outcome Measures
Percentage reduction in plaque calcification and carotid stenosis
Secondary Outcome Measures
Full Information
NCT ID
NCT01923012
First Posted
August 13, 2013
Last Updated
May 24, 2014
Sponsor
Azienda Ospedaliera Sant'Anna
1. Study Identification
Unique Protocol Identification Number
NCT01923012
Brief Title
Phase II Randomized Placebo-controlled Study With Vitamin K2 in Asymptomatic Calcified Carotid Stenosis
Acronym
SCAVIT-K2
Official Title
Phase 2 Study Randomized Placebo Controlled With Vitamin K2 in Asymptomatic Calcified Carotid Stenosis
Study Type
Interventional
2. Study Status
Record Verification Date
May 2014
Overall Recruitment Status
Unknown status
Study Start Date
September 2013 (undefined)
Primary Completion Date
September 2014 (Anticipated)
Study Completion Date
September 2015 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Azienda Ospedaliera Sant'Anna
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Randomized placebo-controlled study with vitamine K2 (Menaquinone-4) in calcified carotid stenosis. We evaluate the plaque remodelling after administration of vitamine, reducing the calcified component.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Carotid Disease, Atherosclerosis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
200 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Vitamin K2
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Vitamin K2 (Menaquinone)
Primary Outcome Measure Information:
Title
Percentage reduction in plaque calcification and carotid stenosis
Time Frame
One year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
carotid stenosis between 50 and 70% (NASCET criteria) with calcified plaque
Exclusion Criteria:
renal and/or hepatic failure
diseases with secondary calcifications
dementia
previous strokes
concomitant use of anticoagulants
concomitant infections
pregnancy or breastfeeding
reduced patient's compliance
12. IPD Sharing Statement
Learn more about this trial
Phase II Randomized Placebo-controlled Study With Vitamin K2 in Asymptomatic Calcified Carotid Stenosis
We'll reach out to this number within 24 hrs